Biotechnology & Life Sciences

Stock Code

BTA

Stock Exchange

ax

Biota Holdings (BTA) is a leading anti-infective drug developer. The Company receives royalties for its discovery of a pharmaceutical drug Relenza and it has key partnerships with other companies for the commercialisation and development of its products. Biota was listed on the Australian Stock Exchange (ASX) on 20th December, 1985 and its headquarter is located in Melbourne.

Stock Code

CUV

Stock Exchange

ax

Clinuvel Pharmaceuticals (CUV) specialises in the manufacturing of biopharmaceuticals and prescription dermatology products. Clinuvel is engaged in the development of its innovative drug candidate afamelanotide. Afamelanotide (CUV1647) is a preventative photoprotective drug intended for use in a range of skin disorders caused by ultra violet (UV) radiations; and cancer related treatments. CUV1647 protects skin from UV radiation (UVR) by stimulating the body’s natural ability to produce eumelanin, the dark pigment of the skin having photoprotective properties.

Stock Code

SPL

Stock Exchange

ax

Starpharma Holdings (SPL) is a world leading developer of nanotechnology-based pharmaceuticals operating in Australia and United States. The Company develops and commercialises dendrimer products for use in pharmaceutical, life-science and other applications. SPL is engaged in the development of nano-scale materials, with a particular focus on the development of topical vaginal microbicides to prevent transmission of genital herpes and human immunodeficiency virus (HIV). The key product brand of the Company is VivaGel, which is the most advanced product included in its pipeline.

Stock Code

PVA

Stock Exchange

ax

pSivida (PVA) is an international bio-nanotech company specialising in the development of drug-delivery products in the healthcare industry, with its core focus on ophthalmology and oncology. pSivida listed on the Australian Stock Exchange (ASX) on 12 June, 2008. It is also listed on NASDAQ (PSDV) and Frankfurt (PSI) stock exchanges. pSividia is included in the NASDAQ Health Care Index (Nasdaq: IXHC) and the Merrill Lynch Nanotechnology Index. pSivida sources its revenue from marketed products.

Stock Code

PXS

Stock Exchange

ax

Pharmaxis (PXS) is a pharmaceutical company specialising in the research, development and commercialisation of therapeutic pharmaceutical products. The Company manufactures specialty products for use in the diagnosis and treatment of chronic respiratory and immune disorders. Pharmaxis was listed on the Australian Stock Exchange on 10th November, 2003. Pharmaxis is based in Sydney, with offices also in the US, UK and China. It listed on the on NASDAQ (symbol PXSL) in August 2005.

Stock Code

SRX

Stock Exchange

ax

Sirtex Medical (SRX) is a biotechnology and medical device company. The Company is principally focused on the research and commercial development of liver cancer treatments using small particle technology. The Company supplies its product to a number of markets in Asia-Pacific, Europe and the United States of America. Sirtex listed on the Australian Stock Exchange (ASX) on 24 August, 2000. The Company has developed an innovative technology for the treatment of liver cancer.

Stock Code

CMQ

Stock Exchange

ax

Chemeq (CMQ) is a research driven veterinary pharmaceutical company engaged in the development, manufacturing and marketing of its product, CHEMEQ polymeric anti-microbial (CHEMEQ). CHEMEQ is used for the prevention and control of diseases caused in feedstock animals, like pigs and poultry by intestinal bacteria. Chemeq listed on the Australian Stock Exchange on 25 August, 1999. The Company believes that its product, CHEMEQ, is effective against multiple microorganisms, such as gram-positive and gram-negative bacteria, bacterial spores, mycobacteria, protozoa, viruses, yeasts and fungi.

Stock Code

CIR

Stock Exchange

ax

Circadian Technologies (CIR) is a biotechnology company engaged in the development and commercialisation of biologics-based therapies for the cure of cancer and other serious diseases. The Company has shifted its focus from biotechnology investment and incubation to the development of angiogenesis-based therapeutics for the treatment cancer and other serious diseases. Circadian listed on the Australian Stock Exchange on 18 April, 1991 and currently it has around AU$59 million in cash.

Stock Code

MBP

Stock Exchange

ax

Metabolic Pharmaceuticals (MBP) is a biotechnology company with around 300 million issued shares. The principal focus of the Company is to take innovative drugs, with strong market potential, through research, formal preclinical and clinical development. MBP developed a drug development platform, for the oral delivery of various injected peptide drugs. This platform offers high potential for use by other companies engaged in the development of peptide drugs together with providing a number of out-licensing opportunities.

Stock Code

AVX

Stock Exchange

ax

Avexa (AVX) is a drug-discovery company principally engaged in the research and development of anti-infectives. Avexa's core focus is on the research, discovery and development of innovative medicines for the cure of the diseases caused by Human Immunodeficiency Virus (HIV) and Vancomycin- and methicillin-resistant bacteria. Avexa listed on the Australian Stock Exchange on 23rd September, 2004 and it is headquartered in Melbourne, Victoria. During 2008 the principal activities of the Company were the conduction of anti-infective pharmaceutical programs and projects.